ECCO News

ECCO News keeps ECCO Members up-to-date on what is going on within the organisation and reports on IBD activities taking place within Europe. Since Spring 2006, ECCO News has maintained the flow of information between Members of the organisation. 

ECCO News is an important part of the European Crohn’s and Colitis Organisation’s ambition to create a European standard of IBD care and to promote knowledge and research in the field of IBD. ECCO Members automatically receive this publication four times a year. 

Editor & Associate Editors

Alessandro Armuzzi
© Alessandro Armuzzi

Nuha Yassin
© ECCO

Ignacio Catalán-Serra
© Ignacio Catalán-Serra

Brigida Barberio
© Brigida Barberio

Spyros Siakavellas
© Spyros Siakavellas

Latest ECCO News Content


15June2022

New SciCom member

Sebastian Zeissig, SciCom Chair and Isabelle Cleynen, SciCom Member

Sebastian Zeissig
© ECCO


Isabelle Cleynen
© ECCO

SciCom announces the recent election of new member Isabelle Cleynen during the ECCO’22 Congress, with a mandate running from 2022 to 2025.

Posted in ECCO News, Committee News, SciCom, Volume 17, Issue 2

15June2022

ECCO Young Researcher Award

Sebastian Zeissig, SciCom Chair

Sebastian Zeissig 
© ECCO

Dear ECCO Friends and Members,

It is with great pleasure and excitement that we announce the brand new ECCO Young Researcher Award 2022. This new ECCO Prize will be awarded to outstanding young researchers in recognition of their excellent contributions to basic and clinical science in the field of IBD. With this prize, ECCO strives to further support the visibility of exceptional young talents in IBD, acknowledge their achievements in the field and facilitate their ongoing and future research.

Posted in ECCO News, Committee News, SciCom, Volume 17, Issue 2

15June2022

Call for Participants: The 21st IBD Intensive Course for Trainees


IBD Intensive Course for Trainees
© ECCO

The 21st ECCO Intensive Course for Trainees designed for residents, fellows in gastroenterology and junior faculty will take place in Copenhagen, Denmark, on March 1, 2022, immediately prior to our next Congress. We are pleased to inform you that the preliminary programme for this course is already available.

Posted in ECCO News, ECCO'23, Congress News, EduCom, Volume 17, Issue 2

15June2022

Call for Participants: The 14th N-ECCO School


N-ECCO School
© ECCO

At the 18th Congress of ECCO in Copenhagen, the Nurses of ECCO (N-ECCO) will host the educational activity for IBD Nurses, N-ECCO School, for the 14th time. ECCO intends to give nurses, who might be still in training and have an interest in IBD, the possibility to attend an IBD-focused course. The ultimate aim of this programme is to improve nurse education throughout Europe.

Posted in ECCO News, ECCO'23, Congress News, Volume 17, Issue 2, N-ECCO

15June2022

Call for abstracts for the 18th Congress of ECCO



To submit an abstract for the 18th Congress of ECCO, use our ECCO Portal.

Please also view important information on the submission process and the guidelines for abstract submission.

Posted in ECCO News, ECCO'23, Congress News, Volume 17, Issue 2

15June2022

18th Congress of ECCO 2023 Copenhagen: Overview of Scientific and Educational Programmes

Alessandro Armuzzi, Brigida Barbeiro and Spyros Siakavellas, ECCO News Editor & Associate Editors

Alessandro Armuzzi
© Alessandro Armuzzi
Brigida Barberio
© Brigida Barberio
Spyros Siakavellas
© Spyros Siakavellas

Dear IBD colleagues and friends,

Warm greetings from the ECCO News Team at the beginning of this hopeful spring, following two very challenging years.

After two years of meeting each other virtually due to the COVID-19 pandemic, we are optimistic that next year we will return to face-to-face interaction at the 18th Congress of ECCO in the vibrant city of Copenhagen. At last, we will able to share and exchange knowledge and ideas in person and not from behind a screen!

Scientific sessions will be held from Thursday to Saturday, March 2–4, 2023, while the Educational Programme will start earlier in the week, on Wednesday, March 1, and will finish at the end of the morning of March 2 in order to allow for a seamless experience with no overlapping sessions and to cater for all delegates. We kindly ask you to take a careful look at the ECCO'23 Congress Website for further details.

Posted in ECCO News, ECCO'23, Congress News, Volume 17, Issue 2

15June2022

ECCO Standpoint on JAK inhibitors in IBD

S. Danese, F. Magro, A. Hart, J. van der Woude, A. Armuzzi, B. Siegmund, L. Peyrin-Biroulet

In a recent randomized trial by Ytterberg and colleagues, called Oral Surveillance, patients with rheumatoid arthritis (RA) aged > 50 years and with at least an additional cardiovascular (CV) risk factor at baseline, treated with tofacitinib 5 or 10 mg twice daily experienced a higher proportion of major adverse cardiovascular events (MACE) and cancer compared with the control group (adalimumab or etanercept) [1]. 

These new data might have crucial implications in ulcerative colitis (UC) where tofacitinib, filgotinib and upadacitinib are approved.

Posted in ECCO News, Volume 17, Issue 2

15June2022

Letter from the ECCO President

Laurent Peyrin-Biroulet, ECCO President


Laurent Peyrin-Biroulet
© ECCO

 

Dear ECCO Friends,

With the summer approaching we hope you enjoy the second Issue of ECCO NEWS where you will find the preliminary scientific programme and our educational Activities at ECCO’23. As usual we offer a wide range of Workshops and Courses for IBD Nurses, surgeons, young gastroenterologists, paediatricians, scientists and allied healthcare professionals.

Posted in ECCO News, Volume 17, Issue 2, Letters from the ECCO President

28April2022

Evolving Treatment Options for Patients with Ulcerative Colitis (UC)

This symposium was sponsored by Bristol Myers Squibb



Presented by:
Axel Dignass, MD, PhD – Frankfurt, Germany
Iris Dotan, MD – Petah Tikva, Israel
James Lindsay, PhD, BM BCh, FRCP – London, UK

Conventional therapies remain the most common first-line treatments for moderate to severe ulcerative colitis (UC) in the EU, including aminosalicylates (5-ASAs), corticosteroids, and immunosuppresants.1 However, clinical remission is not always achieved with conventional therapies in certain patient populations.2 According to one retrospective study of patient-reported outcomes of 256 patients, more than half of patients did not achieve control of clinical measures, such as rectal bleeding or normal stool frequency, with the use of conventional therapies.2

 

Posted in ECCO News, Volume 17, Issue 1, ECCO'22

28April2022

Role of Foods in Crohn’s Disease: Impact on Inflammation and Recovery

This Symposium was sponsored by Nestlé Health Science



Diet is a significant factor in the development of Inflammatory Bowel Disease (IBD) and management of the condition. The Crohn’s Disease Exclusion Diet (CDED) has been shown to be effective in achieving remission, but could it be used more widely?

Increased fibre intake is a key element of CDED, but does it always have a beneficial impact? Recent studies have investigated how CDED impacts the microbiota and whether food additives could contribute to the development of IBD.

jkghjhkljhjkhhlöjkhkljkljlklklklklklkknkjnjknknnkjnklnknknmmmmmmmmmmmmmmmmmmmmmmm

Posted in ECCO News, Volume 17, Issue 1, ECCO'22

Portal